SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant market volatility after a Blue Origin rocket launch failed to place the BlueBird 7 satellite into its intended orbit, forcing the company to de-orbit the unit. While the community is actively debating the reliability of Blue Origin versus SpaceX and worrying about potential delays to the company's 2026 launch cadence, many investors remain bullish on the long-term thesis, noting that the loss is covered by insurance and production for subsequent satellites remains ongoing.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending as traders closely monitor escalating geopolitical tensions in the Middle East alongside conflicting headlines regarding potential peace talks. Market participants are actively debating whether this volatility signals an impending pullback from recent highs or if algorithmic buying and tech earnings momentum will continue to drive a melt-up.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is generating significant market buzz as traders anticipate the signing of a federal executive order focused on fast-tracking ibogaine research for PTSD and addiction treatment. The community is actively debating the stock's potential for a short squeeze, driven by a tight float and the belief that the company's GMP-compliant supply chain positions it as a key beneficiary of new policy tailwinds.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining strong investor attention as the community anticipates potential breakthroughs in its REGAL Phase 3 trial for GPS and upcoming data on SLS009. Discussions are dominated by speculation regarding an imminent readout of survival events, a potential short squeeze fueled by significant institutional interest, and growing confidence in the company's oncology platform.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is rallying sharply after receiving government approval to increase its ownership stake in the Tanbreez rare earth project to 92.5%, a major milestone that strengthens its control over a key strategic asset. The community is buzzing with bullish sentiment and active debate, with many investors pointing to the de-risking of the project and its geopolitical importance as catalysts for a potential short squeeze.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending as the community debates its long-term potential versus short-term volatility, with strong enthusiasm fueled by recent global expansion efforts in Japan and Saudi Arabia. Investors are actively discussing the company's immunotherapy platform, its path toward potential label expansions for Anktiva, and the ongoing struggle against regulatory hurdles while tracking institutional movements.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is seeing significant market activity as investors monitor incoming FDA National Priority Vouchers and a recent executive order aimed at accelerating psychedelic research. While the community is actively debating the stock's potential for growth, breakthrough clinical milestones, and M&A prospects, discussions also center on historical management concerns and dilution risks associated with the company's past operations.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as investors react to a high-profile White House executive order aimed at accelerating psychedelic research and fast-tracking FDA reviews for breakthrough mental health treatments. The community is actively debating the company's status as a late-stage clinical leader, with many highlighting its potential to benefit from the new regulatory landscape as it approaches major clinical milestones and potential commercialization.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Investors are closely watching the iShares MSCI Brazil ETF ($EWZ) as technical indicators and macro tailwinds, such as a weakening US dollar and potential emerging market capital inflows, spark renewed interest. The community remains divided, weighing the allure of high dividend yields and commodities leverage against concerns over political developments and regional economic stability.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp. is trending following its recent NYSE debut as traders capitalize on its position within the high-demand defense and autonomous drone sector. The community is actively debating the stock's momentum potential, weighing strong government contract backing against high volatility and comparisons to other recent IPOs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Cwm LLC

Cwm LLC lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.0% in the fourth quarter, according to the company in its most recent filing with the SEC...

Mirae Asset Global Investments Co. Ltd. Buys 43,302 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 703.0% during the 4th quarter, according to the company in its...

Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities...

Assetmark Inc. Has $6.38 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Assetmark Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 34.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC...

GF Fund Management CO. LTD. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY

GF Fund Management CO. LTD. boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 989.1% in the fourth quarter, according to its most recent filing with the...

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday...

KBC Group NV Has $138.46 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

KBC Group NV increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 27.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 348,194 shares of the biopharmaceutical company's st...

Sumitomo Mitsui Trust Group Inc. Has $130.34 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Sumitomo Mitsui Trust Group Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent filing with...

Truist Financial Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $505.00

Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating for the company in a research note on Monday...

Massachusetts Financial Services Co. MA Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Massachusetts Financial Services Co. MA lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 38.9% during the fourth quarter, according to its most recent...

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

ALNY
Alnylam Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALNY News

ALNYAlnylam Pharmaceuticals Inc